| ritonavir / Generic mfg. |
2016-001440-18: The influence of cytochrome P450 3A4 inhibitors on serum levels of Ivacaftor in cystic fibrosis patients and healthy subjects. De invloed van cytochroom P450 3A4 remmers op bloedspiegels van ivacaftor in patiënten met taaislijmziekte en gezonde vrijwilligers. |
|
|
| Ongoing | 4 | 12 | Europe | Claritromycin, azithromycin, Norvir, Film-coated tablet, Ivacaftor, claritromycin 500mg film coated tablets, Azithromycin 500 mg film-coated tablet, Norvir 100 mg film-coated tablets | university medical center utrecht, University medical center utrecht | cystic fibrosis and healthy subjects, patients with cystic fibrosis and healthy people, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
NCT06337032: A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments |
|
|
| Recruiting | 4 | 350 | RoW | F/TAF (High Dose Tablet), Descovy®, F/TAF (Low Dose Tablet), F/TAF (Lowest Dose Tablet), F/TAF (High Dose TOS), F/TAF (Low Dose TOS), F/TAF (Lowest Dose TOS), E/C/F/TAF, Genvoya®, E/C/F/TAF (Low Dose), Cobicistat (High Dose), GS-9350, Tybost®, Cobicistat (Low Dose), Cobicistat (TOS), B/F/TAF (High Dose), Biktarvy®, GS-9883/F/TAF, B/F/TAF (Low Dose), B/F/TAF (High Dose TOS), B/F/TAF (Low Dose TOS), B/F/TAF (Lowest Dose TOS), 3rd ARV Agent, Nucleos(t)ide reverse transcriptase inhibitors (NRTI), ATV, DRV, Lopinavir Boosted with ritonavir (LPV/r) | Gilead Sciences | HIV-1-infection | 03/34 | 03/34 | | |
| Completed | 3 | 407 | Europe, Canada, US, RoW | Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir | Eiger BioPharmaceuticals | Hepatitis Delta Virus | 10/22 | 03/23 | | |
LOWR6, NCT05229991: Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection |
|
|
| Active, not recruiting | 3 | 30 | RoW | Lonafarnib, LNF, Ritonavir, Norvir | Soroka University Medical Center, Eiger BioPharmaceuticals | Hepatitis D, Chronic | 12/24 | 04/25 | | |
NCT05506176: A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19 |
|
|
| Completed | 2/3 | 1208 | RoW | SIM0417, Simnotrelvir, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | COVID-19 | 01/23 | 03/23 | | |
NCT05656443: Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19 |
|
|
| Completed | 2/3 | 1246 | RoW | GST-HG171/Ritonavir, Placebo | Fujian Akeylink Biotechnology Co., Ltd. | COVID-19 Pneumonia | 05/23 | 07/23 | | |
NCT04147208: Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection |
|
|
| Completed | 2 | 250 | RoW | GLS4, Morphothiadine Mesilate Capsules, RTV, Ritonavir tablet, ETV, Entecavir table | Sunshine Lake Pharma Co., Ltd. | Chronic HBV Infection | 06/22 | 09/23 | | |
| Recruiting | 2 | 400 | Europe | Nirmatrelvir/ritonavir, Paxlovid, Placebo/ritonavir, Placebo | Karolinska Institutet, Karolinska University Hospital, Pfizer | Post-COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19, POTS - Postural Orthostatic Tachycardia Syndrome, Post COVID-19 Condition, Post-COVID Syndrome, Post COVID-19 Condition, Unspecified, Postinfectious Inflammation, Postinfectious Disorder | 01/24 | 03/24 | | |
NCT05369676: To Evaluate SSD8432/ Ritonavir in Adults With COVID-19 |
|
|
| Completed | 1/2 | 32 | RoW | SSD8432 dose 1/Ritonavir, SIM0417 dose 1/Ritonavir, SSD8432 dose 2/Ritonavir, SIM0417 dose 2/Ritonavir | Jiangsu Simcere Pharmaceutical Co., Ltd. | COVID-19 Patients | 08/22 | 08/22 | | |
2021-001029-32: A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 91 | Europe | PBI-200, ritonavir, PBI-200, Tablet, Film-coated tablet, Norvir | Pyramid Biosciences, Inc., Pyramid Biosciences, Pyramid Biosciences, Inc., Pyramid Biosciences | One of the following solid tumors which has progressed on or following at least one systemic therapy regimen administered for advanced or metastatic disease or for which no approved therapy exists:• NTRK-fusion-positive, locally advanced (i.e., not amenable to surgical resection) or metastatic solid tumor• NTRK-gene amplified, locally advanced or metastatic solid tumor (Phase 1 only)• EWSR1-WT1-positive DSRCTs (Phase 1 only), Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors, Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 1/2 | 766 | US, RoW | DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole | DualityBio Inc., BioNTech SE | HER2-positive Advanced Solid Tumor | 04/26 | 10/27 | | |
A104, NCT03383692: Study of DS-8201a for Participants With Advanced Solid Malignant Tumors |
|
|
| Completed | 1 | 40 | Japan, RoW | DS-8201a, Ritonavir, Norvir, Itraconazole, Sporanox, Orungal | Daiichi Sankyo Co., Ltd., AstraZeneca | Neoplasm Metastasis | 09/18 | 09/23 | | |
NCT05829551: The Safety, Tolerability and Pharmacokinetics Study of RAY1216 in Healthy Adult Participants |
|
|
| Completed | 1 | 88 | RoW | RAY1216 dose 1, RAY1216 dose 2, RAY1216 dose 3, RAY1216 dose 4 &ritonavir, RAY1216 dose 5, RAY1216 dose 6, RAY1216 dose 7, RAY1216 dose 8, RAY1216 dose 9, RAY1216 dose 10 | Guangdong Raynovent Biotech Co., Ltd | COVID-19 (Coronavirus Disease 2019) | 08/22 | 08/22 | | |
NCT05458076: A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants |
|
|
| Recruiting | 1 | 86 | RoW | QLS1128 A-Dose 1~5 and Ritonavir, QLS1128 C-Dose 1~3 and Ritonavir, QLS1128 D-Dose 1 and Ritonavir | Qilu Pharmaceutical Co., Ltd. | COVID-19 | 09/22 | 09/22 | | |
NCT05339646: A Phase I Clinical Study of SSD8432 in Healthy Adult Subjects |
|
|
| Recruiting | 1 | 108 | RoW | SSD8432 dose 1~7 and Ritonavir, SSD8432 dose 8~9, SSD8432 dose 10~12 and ritonavir, SSD8432 dose 13 and Ritonavir, SSD8432 dose 14 and Ritonavir | Jiangsu Simcere Pharmaceutical Co., Ltd. | Healthy Participants | 10/22 | 12/22 | | |
| Completed | 1 | 108 | RoW | WPV01 Dose 1-4, WPV01 Dose 5-8 and Ritonavir, WPV01 Dose 9-12, WPV01 Dose 13-15 and Ritonavir, WPV01 Dose 16 | Westlake Pharmaceuticals (Hangzhou) Co., Ltd. | Healthy Participants | 03/23 | 07/23 | | |
NCT05665647: Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Participants |
|
|
| Completed | 1 | 36 | RoW | Cohort 1: SIM0417/ritonavir and itraconazole, Interaction between SIM0417/ritonavir and itraconazole, Cohort 2: SIM0417/ritonavir and rifampicin, Interaction between SIM0417/ritonavir and rifampicin, Cohort 3: SIM0417/ritonavir and midazolam, Interaction between SIM0417/ritonavir and midazolam | Jiangsu Simcere Pharmaceutical Co., Ltd. | Healthy Volunteers | 01/23 | 02/23 | | |
NCT06084507: Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants |
|
|
| Active, not recruiting | 1 | 18 | RoW | GST-HG171/ritonavir, ritonavir | Fujian Akeylink Biotechnology Co., Ltd. | COVID-19 Respiratory Infection | 05/23 | 12/23 | | |
NCT06087055: Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants |
|
|
| Completed | 1 | 12 | RoW | GST-HG171/Ritonavir, Itraconazole | Fujian Akeylink Biotechnology Co., Ltd. | Healthy Participant | 06/23 | 08/23 | | |
NCT05826249: Safety and Pharmacokinetics of SIM0417 Combined With Ritonavir in Healthy Elderly Subjects |
|
|
| Recruiting | 1 | 20 | RoW | SIM0417/Ritonavir, 750 mg SIM0417/100 mg ritonavir | Jiangsu Simcere Pharmaceutical Co., Ltd. | Elder | 09/23 | 11/23 | | |
NCT05731804: Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir |
|
|
| Not yet recruiting | 1 | 72 | RoW | SIM0417 600 mg; Ritonavir100 mg, SIM0417 375 mg; Ritonavir100 mg, SIM0417 750 mg; Ritonavir100 mg | Jiangsu Simcere Pharmaceutical Co., Ltd. | Renal Impairment, Hepatic Impairment | 12/23 | 12/23 | | |
| Not yet recruiting | 1 | 24 | US | Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), MR-Guided LITT, Abacavir, Lamivudine, Ritonavir, Norvir, RTV, Temozolomide, TMZ, Focal Radiotherapy | University of Miami, Medtronic | High Grade Glioma | 05/28 | 05/29 | | |